Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FLGC Flora Growth	$23.50 +17.6%	$24.39	$15.15 ▼ $82.29	$11.54M	1.97	14,772 shs	29,551 shs
QNCX Quince Therapeutics	$1.68 -2.3%	$1.60	$0.51 ▼ $2.45	$92.39M	1.02	217,956 shs	126,612 shs
RENB Renovaro	$0.24 -1.4%	$0.30	$0.22 ▼ $2.10	$41.57M	0.54	1.27 million shs	476,121 shs
VTGN VistaGen Therapeutics	$2.95 +0.7%	$2.48	$1.90 ▼ $3.79	$89.89M	0.4	420,364 shs	232,510 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FLGC Flora Growth	+13.86%	+34.90%	-10.07%	-10.84%	-33.78%
QNCX Quince Therapeutics	-2.33%	+0.60%	-2.89%	+97.65%	+207.24%
RENB Renovaro	-1.45%	+5.78%	-15.00%	-26.09%	-65.40%
VTGN VistaGen Therapeutics	+0.68%	+8.06%	+31.11%	+19.92%	-10.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FLGC Flora Growth	3.1704 of 5 stars	3.3	5.0	3.4	0.8	0.6
QNCX Quince Therapeutics	2.8078 of 5 stars	3.7	3.0	2.3	1.7	0.6
RENB Renovaro	1.8519 of 5 stars	0.0	5.0	3.2	1.7	0.6
VTGN VistaGen Therapeutics	1.0171 of 5 stars	0.0	4.0	1.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FLGC Flora Growth	3.00	Buy	$93.00	295.74% Upside
QNCX Quince Therapeutics	3.30	Buy	$8.14	384.69% Upside
RENB Renovaro	0.00	N/A	N/A	N/A
VTGN VistaGen Therapeutics	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest FLGC, QNCX, RENB, and VTGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	QNCX Quince Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$9.00 ➝ $8.00
8/5/2025	FLGC Flora Growth	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$30.00
8/5/2025	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
8/5/2025	QNCX Quince Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$9.00
8/5/2025	QNCX Quince Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$9.00
7/17/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/18/2025	VTGN VistaGen Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/13/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/4/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FLGC Flora Growth	$59.51M	0.23	N/A	N/A	$6.96 per share	3.38
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	$0.22 per share	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	$0.89 per share	N/A
VTGN VistaGen Therapeutics	$490K	184.71	N/A	N/A	$1.85 per share	1.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FLGC Flora Growth	-$15.91M	-$34.38	N/A	N/A	N/A	-24.86%	-261.57%	-48.06%	N/A
QNCX Quince Therapeutics	-$56.83M	-$1.09	N/A	N/A	N/A	N/A	-187.49%	-42.47%	N/A
RENB Renovaro	-$88.43M	-$0.77	N/A	∞	N/A	N/A	-60.38%	-47.04%	9/29/2025 (Estimated)
VTGN VistaGen Therapeutics	-$51.42M	-$1.78	N/A	N/A	N/A	-6,777.08%	-74.06%	-64.10%	N/A

Latest FLGC, QNCX, RENB, and VTGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	QNCX Quince Therapeutics	-$0.28	-$0.34	-$0.06	-$0.34	N/A	N/A
8/7/2025	Q1 2026	VTGN VistaGen Therapeutics	-$0.47	-$0.47	N/A	-$0.47	$0.22 million	$0.24 million
8/1/2025	Q2 2025	FLGC Flora Growth	-$0.06	-$0.11	-$0.05	-$0.11	$11.77 million	$14.80 million
6/17/2025	Q4 2025	VTGN VistaGen Therapeutics	-$0.52	-$0.43	+$0.09	-$0.43	$0.18 million	($0.01) million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FLGC Flora Growth	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	N/A
VTGN VistaGen Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FLGC Flora Growth	0.50	0.96	0.61
QNCX Quince Therapeutics	1.45	5.00	4.05
RENB Renovaro	N/A	0.13	0.13
VTGN VistaGen Therapeutics	N/A	5.98	6.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FLGC Flora Growth	36.01%
QNCX Quince Therapeutics	30.75%
RENB Renovaro	71.41%
VTGN VistaGen Therapeutics	78.39%

Insider Ownership

Company	Insider Ownership
FLGC Flora Growth	12.56%
QNCX Quince Therapeutics	20.30%
RENB Renovaro	0.50%
VTGN VistaGen Therapeutics	2.85%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FLGC Flora Growth	280	580,000	505,000	Not Optionable
QNCX Quince Therapeutics	60	53.71 million	42.81 million	Optionable
RENB Renovaro	20	172.12 million	171.26 million	Optionable
VTGN VistaGen Therapeutics	40	30.68 million	29.81 million	Optionable

FLGC, QNCX, RENB, and VTGN Headlines

Recent News About These Companies

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call Transcript

August 12 at 5:10 PM | msn.com

VistaGen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Meets Estimates

August 10, 2025 | marketbeat.com

Vistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ...

August 8, 2025 | finance.yahoo.com

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Q1 2026 Vistagen Therapeutics Inc Earnings Call Transcript

August 8, 2025 | gurufocus.com

Vistagen (VTGN) Q1 R&D Expense Jumps 54%

August 7, 2025 | fool.com

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

August 7, 2025 | zacks.com

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

August 7, 2025 | businesswire.com

VistaGen Therapeutics Q1 2026 Earnings Preview

August 6, 2025 | msn.com

VistaGen Therapeutics (VTGN) to Release Earnings on Thursday

August 2, 2025 | marketbeat.com

Vistagen to Present at the BTIG Virtual Biotechnology Conference

July 24, 2025 | businesswire.com

VistaGen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50-Day Moving Average - Time to Sell?

July 16, 2025 | marketbeat.com

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

July 15, 2025 | businesswire.com

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

July 15, 2025 | businesswire.com

Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay

July 3, 2025 | msn.com

VTGN Vistagen Therapeutics, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

June 25, 2025 | businesswire.com

Vistagen Therapeutics, Inc. (VTGN) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript

June 22, 2025 | insidermonkey.com

William Blair Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)

June 20, 2025 | theglobeandmail.com

Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges

June 19, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC, QNCX, RENB, and VTGN Company Descriptions

Flora Growth NASDAQ:FLGC

$23.50 +3.52 (+17.62%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$23.50 0.00 (-0.02%)

As of 08/14/2025 07:59 PM Eastern

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

Quince Therapeutics NASDAQ:QNCX

$1.68 -0.04 (-2.33%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.78 +0.10 (+5.95%)

As of 08/14/2025 07:47 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Renovaro NASDAQ:RENB

$0.24 0.00 (-1.45%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.24 +0.01 (+2.94%)

As of 08/14/2025 07:40 PM Eastern

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

VistaGen Therapeutics NASDAQ:VTGN

$2.95 +0.02 (+0.68%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.95 0.00 (0.00%)

As of 08/14/2025 07:56 PM Eastern

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time